Crinetics Pharmaceuticals, Inc. CRNX

About Crinetics Pharmaceuticals, Inc. (CRNX): stock profile, AI score and financials

Acquired by Vertex Pharmaceuticals Incorporated: Crinetics Pharmaceuticals, Inc. (CRNX) no longer trades and has left 13F Pro's AI-ranked universe. The acquisition closed on September 1, 2026 (SEC 8-K 2.01). Its last closing price was on August 31, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from August 29, 2026. Crinetics Pharmaceuticals, Inc. (CRNX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks CRNX using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q2 2026), Crinetics Pharmaceuticals, Inc. reports quarterly revenue of $25.1M, net income of $-120.9M, free cash flow of $-94.7M. Top institutional holders of CRNX by reported 13-F value include FMR, BlackRock, FARALLON CAPITAL MANAGEMENT, based on the most recent SEC filings. CRNX trades on the Nasdaq exchange and files with the SEC under CIK 1658247. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Crinetics Pharmaceuticals, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1658247 →